Durable response after just one cycle of belotecan-based chemotherapy in a patient with relapsed primary peritoneal serous carcinoma

Authors

  • Guk Jin Lee,

    1. Department of Internal Medicine, Bucheon St Mary's Hospital, The Catholic University School of Medicine, Bucheon, Korea
    Search for more papers by this author
  • Ji Won Min,

    1. Department of Internal Medicine, Bucheon St Mary's Hospital, The Catholic University School of Medicine, Bucheon, Korea
    Search for more papers by this author
  • Min Wu Seo,

    1. Department of Internal Medicine, Bucheon St Mary's Hospital, The Catholic University School of Medicine, Bucheon, Korea
    Search for more papers by this author
  • Mi Yeong Lee,

    1. Department of Internal Medicine, Bucheon St Mary's Hospital, The Catholic University School of Medicine, Bucheon, Korea
    Search for more papers by this author
  • Jong Youl Jin

    Corresponding author
    1. Department of Internal Medicine, Bucheon St Mary's Hospital, The Catholic University School of Medicine, Bucheon, Korea
    • Reprint request to: Dr Jong-Youl Jin, Division of Hematology/Oncology, Department of Internal Medicine, Bucheon St Mary's Hospital, The Catholic University School of Medicine, 327 Sosa-ro, Wonmig-gu, Bucheon-si, Gyeonggi-do 420-717, Korea. Email: drjin@catholic.ac.kr

    Search for more papers by this author

Abstract

The efficacy of second-line chemotherapy for relapsed primary peritoneal serous carcinoma has been numerously reported, but reports on durable response after second-line therapy have been rare. We report the case of a 66-year-old woman with relapsed primary peritoneal serous carcinoma who showed durable response after just one cycle of second-line belotecan-based therapy. The response might be a complete pathologic remission. Considering the fact that our patient suffered from neutropenic sepsis during her treatment, we concluded that belotecan-based chemotherapy could be a good option for second-line chemotherapy in some selected patients, so patient selection should be carefully performed due to the toxicity of belotecan.

Ancillary